1

                                                                    EXHIBIT 99.1


SpectRx, Inc. (770) 242-8723        Financial Relations Board (212) 445-8000


                                                                  
Bill Wells - Media                  Alison Ziegler   Julie Tu              Judith Sylk-Siegel
Thomas H. Muller, Jr. - Financial   General Contact  Analyst Information   Media Contact


SpectRx, Inc. Announces Stock Repurchase Program

         NORCROSS, GA. (September 19, 2001) - SpectRx, Inc. (NASDAQ: SPRX) today
announced that its Board of Directors has approved a stock repurchase program
for up to $1.0 million of the Company's common stock. Shares are expected to be
purchased from time to time in the open market. These purchases may be commenced
or suspended at any time without prior notice depending on business or market
conditions and other factors. SpectRx currently has approximately 10.4 million
shares outstanding.

         SpectRx, a specialty point-of-care medical technology company, develops
and manufactures non-invasive and minimally invasive diagnostic and monitoring
systems. The Company employs leading-edge biophotonics, or the use of light and
spectral energies, to develop painless point-of-care alternatives to blood- and
tissue-based procedures. Through internal product development and partnerships
with major health care companies, SpectRx focuses on key niche and large
diagnostic markets, primarily oncology, endocrinology and neonatology. The
Company's handheld, FDA-cleared BiliChek(TM) (sold internationally as
BiliCheck(TM)) is the first commercially available non-invasive painless monitor
for infant jaundice. Under development are products for the non-invasive
detection of cervical cancer and Type II diabetes, and a consumer device for
continuous glucose monitoring. For more information, visit SpectRx's web sites
at www.spectrx.com and www.bilicheck.com, or use Internet keyword spectrx.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995. A number of the matters and subject areas discussed in this press release
that are not historical or current facts deal with potential future
circumstances and developments. The discussion of such matters and subject areas
is qualified by the inherent risks and uncertainties surrounding future
expectations generally and also may materially differ from SpectRx's actual
future experience involving any of or more of such matters and subject areas.
SpectRx has attempted to identify, in context, certain of the factors that they
currently believe may cause actual future experience and results to differ from
SpectRx's current expectations regarding the relevant matter or subject area.
Such risks and uncertainties include: the early stage of its products in
development, its dependence on collaborative arrangements, its continued ability
to use and sublicense intellectual property, the uncertainty of market
acceptance of its products, the intense competition in the medical device
industry, the uncertainty of regulatory approval of its products, the
uncertainty of legal proceedings, as well as those that are more fully described
from time to time in SpectRx's reports under the heading "Risk Factors" filed
with the SEC, including SpectRx's Annual Report on Form 10-K for the fiscal year
ended December 31, 2000 and in the Forms 10-Q for the first and second quarter
of 2001 filed by SpectRx.